Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.42 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LOX | P28300 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1494554 | 0.81 | TDP1 (0.55) | LMNAALDH1A1SMN1; SMN2HTTKDM4E | |
| SCHEMBL2802110 | 0.79 | LMNA (0.68) | LMNAALDH1A1SMN1; SMN2HTTKMT2A | |
| SCHEMBL11014092 | 0.79 | SMN1; SMN2 (0.47) | LMNAALDH1A1SMN1; SMN2HTTCYP2A6 | |
| SCHEMBL22042464 | 0.79 | ALDH1A1 (0.51) | ALDH1A1KDM4EKMT2A | |
| SCHEMBL11711969 | 0.78 | LMNA (0.50) | LMNAALDH1A1SMN1; SMN2HTTKDM4E | |
| SCHEMBL11711975 | 0.78 | LMNA (0.50) | LMNAALDH1A1SMN1; SMN2HTTKDM4E | |
| SCHEMBL2801033 | 0.77 | CA12 (0.67) | LMNASMN1; SMN2HTTKDM4EKMT2A | |
| SCHEMBL5891165 | 0.77 | LMNA (0.64) | LMNAALDH1A1SMN1; SMN2HTTKDM4E | |
| SCHEMBL5890969 | 0.77 | LMNA (0.64) | LMNAALDH1A1SMN1; SMN2HTTKDM4E | |
| SCHEMBL2224577 | 0.76 | RAB9A (0.51) | LMNAALDH1A1SMN1; SMN2HTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12578335-B2 | Bioprobes for lysyl oxidases and uses thereof | SYNTARA LIMITED (AU) | 2026-03-17 | — | — | US | disclosed |
| WO-2025228900-A1 | ARYLAMIDE SUBSTITUTED INDAZOLES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-11-06 | — | — | WO | disclosed |
| US-20230349907-A1 | BIOPROBES FOR LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2023-11-02 | — | — | US | disclosed |
| US-20230349907-A1 | BIOPROBES FOR LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2023-11-02 | — | — | US | disclosed |
| US-20230349907-A1 | BIOPROBES FOR LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2023-11-02 | — | — | US | disclosed |
| US-20230142739-A1 | PROTEIN-PROTEIN INTERACTION STABILIZERS | UNIV CALIFORNIA (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4125861-A2 | PROTEIN-PROTEIN INTERACTION STABILIZERS | The Regents of the University of California (US) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021203016-A2 | PROTEIN-PROTEIN INTERACTION STABILIZERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021155439-A1 | BIOPROBES FOR LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021155439-A1 | BIOPROBES FOR LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2021-08-12 | — | — | WO | disclosed |
| WO-2008138920-A1 | DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-20 | — | — | WO | disclosed |
| US-20080287458-A1 | Dihydroquinone and dihydronaphthridine inhibitors of JNK | ROCHE PALO ALTO LLC | 2008-11-20 | — | — | US | disclosed |
| EP-1748980-A1 | PYRROLIDINE DERIVATIVES AS CB1-RECEPTOR ANTAGONISTS | TANABE SEIYAKU CO., LTD. (JP) | 2007-02-07 | — | — | EP | disclosed |
| WO-2006093518-A2 | THIENYL COMPOUNDS FOR TREATING VIRUS-RELATED CONDITIONS | APATH, LLC (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2005115977-A1 | PYRROLIDINE DERIVATIVES AS CB1-RECEPTOR ANTAGONISTS | TANABE SEIYAKU CO., LTD. (JP) | 2005-12-08 | — | — | WO | disclosed |
| WO-2003042198-A1 | ISOTHIAZOLE DERIVATIVES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2003-05-22 | — | — | WO | disclosed |
| US-4390693-A | BACTERICIDE | MERCK & CO., INC. (US) | 1983-06-28 | — | — | US | disclosed |
| US-4255423-A | BACTERICIDES | MERCK & CO., INC. (US) | 1981-03-10 | — | — | US | disclosed |
| US-4125530-A | FROM 1,1-DIHALO-3,3,3-TRIFLUOROACETONE, BASE, AMMONIA AND A CARBOXALDEHYDE | MERCK & CO., INC. (US) | 1978-11-14 | — | — | US | disclosed |
| US-4032522-A | ANTI-GOUT, ANTI-HYPERURICEMIC | MERCK & CO., INC. (US) | 1977-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230349907-A1 | BIOPROBES FOR LYSYL OXIDASES AND USES THEREOF | MAOB, LOX, LPO | LMNA 2086/4885ALDH1A1 367/4885SMN1; SMN2 4690/4885 |
| US-20230142739-A1 | PROTEIN-PROTEIN INTERACTION STABILIZERS | HSPBP1, HSPA8, HSPH1 | LMNA 2827/4885ALDH1A1 3889/4885SMN1; SMN2 1672/4885 |
| US-12578335-B2 | Bioprobes for lysyl oxidases and uses thereof | LOXL1, LOX, LOXL2 | LMNA 1273/4885ALDH1A1 482/4885SMN1; SMN2 4522/4885 |
| US-20080287458-A1 | Dihydroquinone and dihydronaphthridine inhibitors of JNK | MAPK9, MAPK10, MAPK1 | LMNA 3935/4885ALDH1A1 3819/4885SMN1; SMN2 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.